PROTIA INC. Logo

PROTIA INC.

Develops IVD kits and instruments for allergy, POCT, infectious & autoimmune diseases.

303360 | KO

Overview

Corporate Details

ISIN(s):
KR7303360002
LEI:
Country:
South Korea
Address:
서울특별시 강서구 양천로 401, 강서한강자이타워 A동 702호, 강서구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

PROTIA INC. is an in vitro diagnostics (IVD) company that designs, develops, and manufactures a wide range of diagnostic kits and instruments. Leveraging patented technologies and proteomics-based biomarker research, the company offers solutions across multiple medical fields, including allergy, point-of-care testing (POCT), infectious diseases, autoimmune disorders, cancer, and animal diagnostics. PROTIA is particularly recognized for its high-performance multiplex allergy diagnostic kits, such as the PROTIA Allergy-Q series. The company also developed the world's first total IgG quantitative POCT kit using whole blood. In addition to its products, PROTIA provides specialized protein analysis and custom research services, including protein identification, characterization, and rapid kit development.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-01 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-08-12 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-07-22 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-07-18 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 14.5 KB
2025-05-09 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB
2025-04-04 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 20.4 KB
2025-03-18 00:00
Audit Report / Information
감사보고서제출
Korean 18.4 KB
2025-03-18 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.3 MB
2025-03-11 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 170.9 KB
2025-02-24 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 10.9 KB
2025-01-24 00:00
Regulatory News Service
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.0 KB
2025-01-09 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.4 KB
2024-12-13 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.3 KB
2024-11-27 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 188.1 KB

Automate Your Workflow. Get a real-time feed of all PROTIA INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PROTIA INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PROTIA INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Monopar Therapeutics Logo
Clinical-stage biotech developing radiopharmaceuticals for oncology and therapies for rare diseases.
United States of America
MNPR
Monte Rosa Therapeutics, Inc. Logo
Develops molecular glue degraders to target undruggable proteins in cancer and immune diseases.
United States of America
GLUE
Develops LNP drug delivery systems for severe diseases, offering R&D to GMP manufacturing support.
South Korea
322970
MORISHITA JINTAN CO.,LTD. Logo
Manufactures health products and provides OEM/ODM services using advanced encapsulation technology.
Japan
4524
MUROMACHI CHEMICALS INC. Logo
A diversified manufacturer of pharmaceuticals, chemical systems, health foods & functional materials.
Japan
4885
MUSTANG BIO, INC. Logo
Developing CAR T-cell and gene therapies for cancers and rare genetic disorders.
United States of America
MBIO
MYUNGMOON PHARM CO.,LTD Logo
Develops, manufactures, and commercializes prescription & OTC medicines for global markets.
South Korea
017180
Nanexa AB Logo
Develops long-acting injectables using its proprietary nanotechnology for its own pipeline and partners.
Sweden
NANEXA
Nanobiotix Logo
Develops a first-in-class radioenhancer to amplify radiotherapy's effect directly within tumors.
France
NANO
Nanobiotix S.A. Logo
Developing a nanotherapeutic radioenhancer that amplifies radiation to destroy solid tumors.
United States of America
NBTX

Talk to a Data Expert

Have a question? We'll get back to you promptly.